Company: IOBT
Filing Date: 2025-05-23
Form Type: S-3
Source: 0001193125-25-125831
Chunk: 9

Company: IO Biotech, Inc.
Filing Date: 2025-05-23
Form: S-3
Chunk 9
---
2200 Copenhagen N, Denmark, and our telephone number is +45 7070
2980. Our website address is iobiotech.com, on which we make available, free of charge, our annual report on 10-K, quarterly reports on 10-Q, and any amendments to those
reports filed or furnished pursuant to Section 13(a) or 15(d) as soon as reasonably practicable after we electronically file or furnish such materials with the SEC. Information contained on, or that can be accessed through, our website is not
incorporated by reference into this Annual Report on Form 10-K, and you should not consider information on our website to be part of this Annual Report on Form 10-K. The
SEC also maintains a website that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC, which can be accessed at www.sec.gov.

4

THE OFFERING

| Common stock offered by the selling stockholders | Up to 5,623,664 shares of our common stock issuable upon the exercise of Warrants held by the selling stockholders. |

| Common stock currently outstanding | 65,880,914 (as of May 19, 2025) |

| The Warrants | The Warrants are immediately exercisable upon issuance at an exercise price of $0.8891 per share, subject to adjustments as set forth therein. The Warrants terminate on the earlier of (i) the date that is twenty years following the issuance 
 and (ii) one day prior to the closing of an Acquisition (as defined in the Warrants).                                                                                                                                                            |

| Selling stockholders | All of the shares of our common stock are being offered by the selling stockholders. See “Selling Stockholders” on beginning on page 11 for additional information on the selling stockholders. |

| Use of Proceeds | We will not receive any proceeds from the sale of the shares in this offering by the selling stockholders, although we may receive proceeds from the cash exercise of any Warrants. See “Use of Proceeds” beginning on page 10 for 
 additional information on the use of proceeds.                                                                                                                                                                                     |

| Registration Rights | Under the terms of the Registration Rights Agreement with the selling stockholders, we have agreed to file the registration statement of which this prospectus forms a part in order to register the resale by the selling stockholders of the shares 
 of our common stock offered hereby. See “Selling Stockholders” beginning on page